VNDA (Vanda Pharmaceuticals) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNDA Vanda Pharmaceuticals Inc VNDA
74 GF Score
Price $5.55
GF Value $5.55
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

VNDA
74GF Score
Vanda Pharmaceuticals Inc VNDA
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued. The current stock price of $5.55 is trading 0.1% below its estimated GF Value™ of $5.55. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for VNDA:

  • Short Ratio:
  • GF Value™: $5.55 vs. price of $5.55 (0.1% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
74GF Score

Get the complete analysis for VNDA

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.55
Price
$5.55
GF Value